Today, we feature GMDx a genomics testing company that delivers the next generation of immunogenomic diagnostics in oncology.
Also, outlined below are some of the benefits of raising capital via the PrimaryMarkets Platform. For more information about Capital Raising Click Here .
An exciting business update from GMDx:
- GMDx releases Genomic Data Services “GDS” to the market in partnership with Oracle.
- GMDx have achieved a very success Proof of Concept for the early detection of Alzheimer’s with a new Genomic Application, and new patents have been
lodged by GMDx for this potential breakthrough. GMDx has now entered into a collaboration with the CRC for Mental Heath and are working closely
with The Florey and CSIRO as part of the CRC for Mental Health. GMDx is currently undertaking analytics on a large patient dataset and expects
to scientifically validate this genomic application in coming weeks.
GMDx is a genomics testing company that delivers the next generation of immunogenomic diagnostics in oncology. GMDx was established in 2015 to further develop and commercialise the discoveries of Dr Robyn Lindley. GMDx has developed a comprehensive and powerful genomic-profile testing platform with the clinical applications in oncology for:
- predicting patient response to immunotherapy treatment and
- predicting cancer progression.
The GMDx platform technology combines proprietary predictive algorithms, a strong and extensive IP portfolio, sophisticated analytics and machine learning
capabilities that provide customers with clinical grade whole genome testing.
GMDx is an Australian company raising A$1.7M, for more Information Click Here.
To view all the latest Capital Raising on the Platform Click Here